RxDoctor Payments DataLook up a doctor →

Ajay Sharma, MD

Psychiatry · Zanesville, OHNPI 1336287002

Payments from drug & device makers

$445,927in general payments, 2019–2025

Across 1,693 payments — averaging $263.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$163K
  • Axsome Therapeutics, Inc.$72K
  • Supernus Pharmaceuticals, Inc.$49K
  • Boehringer Ingelheim International GmbH$42K
  • Neurocrine Biosciences, Inc.$41K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$29K
  • plus $49K from 31 others

What the payments were for

  • Consulting fees$70,35818%
  • Speaking & faculty fees$271,08369%
  • Travel & lodging$23,6016%
  • Food & beverage$29,7418%
  • Education$720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$445,927 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$107,485
Medicare patients
144
Services billed
896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate36$304,442
Invega SustennaPaliperidone Palmitate47$158,543
LybalviOlanzapine/Samidorphan Malate40$65,167
AristadaAripiprazole Lauroxil26$64,848
AuvelityDextromethorphan Hbr/Bupropion31$20,657
Quetiapine Fumarate ErQuetiapine Fumarate33$16,096
TrintellixVortioxetine Hydrobromide20$14,986
VyvanseLisdexamfetamine Dimesylate17$6,752
Paliperidone ErPaliperidone33$6,587
Divalproex Sodium ErDivalproex Sodium82$5,440
Clomipramine Hcl23$4,584
Quetiapine Fumarate286$4,567
QelbreeViloxazine Hcl13$4,421
Duloxetine Hcl220$3,373
Olanzapine OdtOlanzapine15$3,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$41,341$304,44236 claims
Johnson & JohnsonInvega Sustenna$474$158,54347 claims
Alkermes, Inc.Lybalvi, Aristada$163,430$130,01566 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$1,938$21,73837 claims
Axsome Therapeutics, Inc.Auvelity$72,165$20,65731 claims
Supernus Pharmaceuticals, Inc.Qelbree$48,861$4,42113 claims
Almatica Pharma LLCSertraline Hcl$39$1,715303 claims
Teva Pharmaceuticals USA, Inc.Loxapine$482$1,23514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Zanesville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →